Abstract
Therapeutic strategies using cytokines have not been extensively tested in patients with advanced non-small-cell lung cancer (NSCLC). We developed a basic laboratory and clinical research program to investigate the effective immunotherapeutic manipulations for activating the endogenous immune system with biological agents. Our efforts using low-dose interleukin 2 in conjunction with other biologic response modifiers for the treatment of NSCLC are summarized here.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 197-201 |
| Number of pages | 5 |
| Journal | Journal of the National Cancer Institute. Monographs |
| Issue number | 13 |
| State | Published - 1992 |
| Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research